Goddard Andrew W, Shekhar Anantha, Whiteman Aaron F, McDougle Christopher J
Department of Psychiatry, Indiana University School of Medicine, University Hospital, UH3124, 550 North University Boulevard, Indianapolis, IN 46202, United States.
Drug Discov Today. 2008 Apr;13(7-8):325-32. doi: 10.1016/j.drudis.2007.12.009. Epub 2008 Feb 14.
Obsessive-compulsive disorder (OCD) is a disabling psychiatric condition affecting 1-2% of the community. Although modern drug, behavioral and psychosurgical therapies have improved the prognosis of OCD considerably, approximately 30% of patients remain treatment-refractory. Currently, selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the drug treatments of choice for OCD. Accordingly, this review evaluates the evidence for a role of the serotonin (5-HT) neurochemical system in the treatment and pathophysiology of OCD. However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects.
强迫症（OCD）是一种致残性精神疾病，影响着1%-2%的人群。尽管现代药物、行为和精神外科治疗已显著改善了强迫症的预后，但仍有约30%的患者对治疗无反应。目前，选择性5-羟色胺（5-HT）再摄取抑制剂（SSRIs）是治疗强迫症的首选药物。因此，本综述评估了5-羟色胺（5-HT）神经化学系统在强迫症治疗和病理生理学中作用的证据。然而，也简要讨论了改变相关神经化学系统（如多巴胺和谷氨酸系统）功能的药物治疗方法，因为它们有望补充和增强SSRI的治疗效果。
